



# VIRTUAL BTOG 2022

20<sup>TH</sup> BTOG ANNUAL CONFERENCE

THURSDAY 27<sup>TH</sup> & FRIDAY 28<sup>TH</sup> JANUARY 2022 | #BTOG22

**Continuing Professional Development – Accreditation approved from The Federation of the Royal Colleges of Physicians of the United Kingdom for 10 CPD Credits (ref 138772) for 4 weeks after the even.**

**Application for approval beyond 4 weeks is in progress. The information was up-to-date at the time of the presentation but does not consider material published since then.**

## Recorded on Thursday 27<sup>th</sup> January 2022

### BTOG Journal Club Review (1 hour)

**Chair:** Allan Hackshaw      **BTOG Trainee Reps:** Adam Januszewski and Helen McDill  
15 mins per speaker and 5 mins for questions

**Paper:** Systemic therapies: IMpower 010 - Adjuvant atezolizumab after adjuvant chemotherapy in resected stage 1B-IIIa non-small cell lung cancer. Felip et al.      **Expert:** Riyaz Shah

**Paper:** Radiotherapy: LungART - Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small cell lung cancer and proven mediastinal N2 involvement. Le Pechoux et al.      **Expert:** John Conibeare

**Paper:** Respiratory: Lung Cancer mortality reduction by LCDT screening: UKLS randomised trial results and international meta-analysis. Field et al.      **Expert:** Emma O'Dowd

### Session 1: Plenary Session (1 hour 50 minutes)

<b>Chair:</b>	<b>Sanjay Popat</b>	
09:00	Welcome – BTOG Steering Committee Chair	Sanjay Popat
09:10	BTOG 2022 Lifetime Achievement Award Presentation	James Spicer
09:20	Lung cancer: state of the nation	Neal Navani
09:35	The route back to 25 by 25	Robert Rintoul
09:50	ETOP Update	Rolf Stahel
10:05	EORTC Update	Anne-Marie Dingemans
10:20	NCRI Update	Matthew Hatton
10:35	Year in Review Panel Discussion	10:50      Close

### Session 2: Oral Abstract Presentations (1 Hour)

<b>Chairs:</b>	<b>Tom Newsom-Davis, Karen Clayton and Helen McDill</b>	
12:00	Rates of acceptance between opt-out vs opt-in smoking cessation referral strategies among current smokers attending a Lung Health Check offering lung cancer screening	Evangelos Katsampouris
12:10	Utilizing Mutational Signatures to Investigate the Effect of Radiotherapy on Lung Cancer Evolution	Kerstin Thol
12:20	Use of Systemic Anti-Cancer Treatments in advanced stage non-small cell lung cancer during the SARS-CoV-2 pandemic in England and Wales: An Analysis of the Rapid Cancer Registration Dataset	Helen Morgan
12:30	An integrated physiotherapy service for patients undergoing treatment for advanced thoracic cancers – an evaluation focusing on the patients' perspectives	Catherine Sandsund
12:40	Q&A	13:00      Close

## Session 3: Specialty Sessions (1 hour per session)

### Translational Oncology

**Chairs:** James Spicer and Shobhit Baijal

14:00	RNA therapeutics for cancer	Debashis Sarker
14:15	Immunotherapy: what's next?	Anna Minchom
14:30	Vaccines revisited	Christian Ottensmeier
14:45	Panel Discussion	
15:00	Close	

---

### Radiotherapy

**Chairs:** Clive Peedell and Stephen Harrow

'Is concurrent chemoradiotherapy follow by surgery standard of care for resectable NSCLC?'

14:00	Oncology perspective	Anna-Maria Shiarli
14:10	Surgical perspective	Doug West
14:20	Panel Discussion	

RCR Lung Cancer Consensus Statement:

14:30	Survey on Implementation	Jonathan McAleese
14:35	Peer Review	Petra Jankowska
14:45	ProKnow	Bojidar Goranov
14:55	Panel Discussion	
15:00	Close	

---

### Respiratory Medicine & Radiology: Missed Lung Cancer

**Chairs:** Emma O'Dowd and Rachel Magennis

14:00	It's not about the errors, it's about the learning	Rachel Magennis
14:10	Duty of Candour	Chris Hammond
14:20	Case Study 1 and Panel Discussion ( <a href="#">link to HSIB report</a> )	Madava Djearaman
14:35	Case Study 2 and Panel Discussion ( <a href="#">link to HSIB report</a> )	Matthew Callister

MDT Panel:

Radiology Rachel Magennis and Chris Hammond

Respiratory Emma O'Dowd and Beth Sage

HSIB Melanie Ottewill, HSIB

14:50	The Healthcare Safety Investigation Branch (HSIB) reports and summary of discussion	Beth Sage
-------	-------------------------------------------------------------------------------------	-----------

---

## Session 4: Cancer Profiling (1 hour)

**Chair:** Angeles Montero and Ramesh Bulusu

16:00	What happens in the molecular lab	Teodora Radonic
16:15	How to understand an NGS report	Alastair Greystoke
16:30	"But my patients all smoke" Does genotyping really matter?	Riyaz Shah
16:45	Panel Discussion	
17:00	Close	

## Session 5: UK Sub-group Sessions (1 hour per session)

### BTOG – NCRI Advanced Disease

<b>Chair:</b>	<b>Fiona Blackhall</b>	
17:00	The NCRI Lung Research Group Advanced Disease Trials Portfolio and Strategy:	Fiona Blackhall
	Focus on National Trials in set up for Advanced NSCLC	
17:10	REFINE-LUNG	Ehsan Ghorani
17:25	TOURIST	David Woolf
17:40	RAMON	Eric Lim
17:50	Panel Discussion: What is involved for patients and how can we encourage participation? Including Lynn Calman, Samreen Ahmed, Janette Rawlinson	

### BTOG – NCRI Mesothelioma

<b>Chair:</b>	<b>Peter Szlosarek</b>	
17:00	Introduction	Peter Szlosarek
17:10	HIT-Meso Proton Trial	Kimberley Durno/ Crispin Hiley
17:30	MIST and NERO update	Dean Fennell
17:45	RSO-021 Trial	Dean Fennell
17:50	Q&A	Peter Szlosarek

### BTOG – NCRI Screening & Early Diagnosis

<b>Chair:</b>	<b>Philip Crosbie</b>	5 minutes Q&A each speaker	
17:00	Trial update: iDx-Lung Study – Update		Jocelyn Walters
17:10	Prevention: Optimising smoking cessation in lung cancer screening		Rachael Murray
17:30	Early Detection: Calculating lung cancer risk using primary care data		Emma O'Dowd
17:45	Trainee talk: Population based invitational strategy to lung cancer screening		Patrick Bradley

### BTOG – NCRI LocoRegional Disease (LORD)

<b>Chair:</b>	<b>Mary O'Brien</b>	15 minutes & 5 minutes Q&A per speaker	
17:00	Proposed metrics to address the low rate of radical treatment of stage III disease		Fiona McDonald
17:20	Frequency of scanning after radical treatment		Michael Davidson
17:40	The place of MRD testing post chemoRT		Nadza Tokaca/Hazel O'Sullivan

### BTOG – Lung Cancer Nursing UK

<b>Chairs:</b>	<b>Jackie Fenemore and Cathy Henshall</b>	
17:00	Introduction	Jackie Fenemore and Cathy Henshall
17:05	Impact of Covid 19 on mesothelioma and lung cancer specialist/advance practice nurses in the UK - a survey of views and experiences since January 2021	Sarah Hargreaves
17:30	Research findings from The Pearl Study on Patient Experience of symptoms, Help Seeking and Risk Factors in Never, Current and Former Smokers with Lung Cancer	Georgia Black
17:50	Launching the Lung CNS Professional Framework Document <i>Crucial, Complex and Caring</i>	Josie Roberts
17:55	Summary	Jackie Fenemore and Cathy Henshall

**Session 6: Optimizing Outcomes Update (1 hour 50 minutes)**

<b>Chairs:</b>	<b>Robert Rintoul and Helen Powell</b>	
09:00	Circulating biomarkers for early-stage lung cancer: how near are we to a useful test?	Frank McCaughan
09:20	Participation and retention in screening - future challenges for a national programme	Samantha Quaife
09:40	Recent advances and controversies in malignant pleural disease	Selina Tsim
10:00	Prehabilitation before treatment of early-stage lung cancer – time for routine commissioned services?	Matthew Evison
10:20	Panel Discussion	
10:50	Close	

**Session 7: Operable NSCLC (1 hour)**

<b>Chairs:</b>	<b>Meenali Chitnis and Ehab Bishay</b>	
12:00	Patient selection for perioperative systemic therapy	Nicolas Girard
12:15	VATS, RATS, MIO: optimal surgical approach to guarantee R0	John Edwards
12:30	What we learned from NADIM	Mariano Provencio
12:45	Panel Discussion	
13:00	Close	

**Session 9: Closing Session (1 hour 15 minutes)**

<b>Chairs:</b>	<b>David Gilligan and Toby Talbot</b>	
16:00	SCLC therapeutics: new roads ahead	Melanie Mackean
16:15	Is immunotherapy for mesothelioma standard?	Paul Baas
16:30	Improving outcomes for senior patients	Fabio Gomes
16:45	Panel Discussion	
17:00	BTOG Poster Prizes 2022 – Announcement	Matthew Callister
<b>17:10</b>	<b>BTOG Steering Committee Chair's Closing Message</b>	<b>Sanjay Popat</b>